Butler addresses how primary care can help manage the burdens of itch in their older patients and offers pearls for consulting and referring to dermatology.
Benjamin Ungar, MD, discusses his presentation at AAD 2025 covering advances and updates about rosacea and seborrheic dermatitis.
AAD 2025. Peter Lio, MD, from the Feinberg School of Medicine in Chicago, says, skip the elimination diet because food is rarely a cause of atopic dermatitis.
There are 3 classes of nonsteroidal topical therapies for atopic dermatitis that target the specific underlying pathophysiology of the skin disease. Shahriari provides a primer as physicians prepare for AAD 2025.
Panelists discuss how proper application technique and adherence are vital for topical atopic dermatitis treatments. Effective provider communication and primary care provider/dermatologist collaboration optimize patient outcomes through education and coordinated care. Primary care providers and dermatologists should coordinate care through clear communication, shared protocols, and defined referral pathways to optimize atopic dermatitis management and improve patient outcomes.
Panelists discuss how, based on clinical observations, atopic dermatitis imposes significant physical and mental burdens. Patients experience chronic itching, pain, and sleep disruption while experiencing psychological distress, social anxiety, and reduced self-esteem. Delayed diagnosis exacerbates these burdens, allowing disease progression and worsening quality of life.
Panelists discuss recent topical atopic dermatitis therapies, which include roflumilast (PDE4 inhibitor, age ≥ 6 years), ruxolitinib (JAK inhibitor, age ≥ 12 years), and tapinarof (hydrocarbon receptor agonist, age ≥ 2 years). Treatment selection considers disease severity, age, affected areas, comorbidities, and previous therapy responses.
Panelists discuss how the newer topical agents (PDE4 inhibitors, JAK inhibitors) demonstrate comparable efficacy to midpotency corticosteroids but with improved safety profiles, lacking steroid-related adverse effects such as skin atrophy, hypothalamic-pituitary-adrenal axis suppression, and tachyphylaxis when used long term.
Shahriari, assistant clinical professor of dermatology at Yale University School of Medicine, says greater understanding of the condition has expanded the population for the diagnosis.
Panelists discuss how older topical treatments such as corticosteroids, calcineurin inhibitors, and crisaborole have limited efficacy with prolonged use. Corticosteroids cause skin thinning and systemic absorption on large body surface area (BSA). Calcineurin inhibitors and crisaborole show modest efficacy, with application site reactions.
Panelists discuss how atopic dermatitis diagnosis in primary care relies on clinical features including pruritus, characteristic distribution, and chronic/relapsing course. Severity assessment involves examining extent, intensity, impact on quality of life, and response to previous treatments.
Not all atopic dermatitis requires treatment by a specialist, says this dermatologist, and she collaborates regularly with her primary care colleagues.
Monu Khanna, MD, discusses challenges in managing pain in patients with obesity, effective pharmacological and nonpharmacological therapies, and more.
Shagun Bindlish, MD, discusses the complex interplay between obesity and mental health conditions and how sex is a potential moderating factor.
Anila Chadha, MD, highlights key preventive strategies to reduce CVD risk in patients with obesity and how to tailor them to address individual patient needs.
More consistent use of evidence-based guidelines and individualized pain management for every patient lead the hopes Edward Mariano, MD, MAS has for the future.
Edward Mariano, MD, MAS, looks at the risk of acute pain transitioning to a chronic condition and how a new nonopioid for acute pain might work for the latter.
Multimodal pain management expert and researcher Mariano describes the NaV1.8 inhibitor as "working in concert" with nonopioid therapies, including nerve blocks.
An anesthesiologist and renowned investigator in use of nonopioids as part of multimodal pain management, Edward Mariano, MD, MAS, describes slow uptake in the field.
William Grady, MD, coauthor of the ECLIPSE trial, discusses how the Shield cfDNA blood-based test compares to traditional CRC screening methods.
Opioid prescribing has seen its extremes, from the 5th Vital Sign era in the aughts to the CDC restrictions of 2016. Mariano talks about the environment right now.
William Grady, MD, coauthor of the ECLIPSE study, discusses the use of non-invasive cfDNA blood-based tests for CRC screening in older adults.
Brexpiprazole and sertraline showed promise for PTSD treatment in a recent study. Lead author, Lori Davis, MD, discusses clinical findings, treatment guidelines, and future research directions.
Suzetrigine (Journavx) PI Todd Bertoch, MD, identifies the sweet spot where he thinks the new NaV1.8 inhibitor will be most effective in post-surgical and other moderate-to-severe acute pain.
Agitation is the most common disabling neuropsychiatric symptom experienced by individuals with Alzheimer dementia; Grossberg explains how common in this short interview.
Anila Chadha, MD, talks to Patient Care about how antiobesity medications can aid in reducing CVD risk in patients with obesity.
William Grady, MD, highlights ongoing efforts to improve test sensitivity and developments of new blood-based tests for early detection of CRC.
Robert Hopkins, Jr, MD, says of official communications during the COVID-19 pandemic that not enough was explained to the public about policy shifts, leaving people wondering.
Mariano, a well-known researcher in regional anesthesiology and acute pain medicine, talks about the Journavx difference, including the drug's safety profile.
Todd Bertoch, MD, reviews the significant findings on relief of pain from the 2 pivotal studies and lauds the remarkable safety profile of the novel nonopoid analgesic Journavx.
